PDA ECHO: INSULIN THERAPY IN PREGNANT WOMENCynthia Halili-Manabat, M.D., PhD<br />Internal Medicine<br />October 2010<br />
abstract<br />goal in pregnancy complicated by diabetes is to maintain maternal glucose levels as near normal as possible ...
abstract<br />only human NPH insulin, regular human insulin and the rapid acting insulin analogs, lispro and aspart, are a...
abstract<br />the total daily insulin dose may be computed based on the current weight of the patient and stage of pregnan...
Fetal Hyperinsulinemia<br />LGA or macrosomia are associated with birth trauma (shoulder dystocia)<br />0.6-1.4% in fetuse...
Management of Hyperglycemia in Pregnancy<br />CGMS<br />mean fasting glucose 75mg/dL<br />peak post-prandial glucose 110mg...
When to Start Insulin<br />When MNT fails<br />Glycemic goals:<br />Premeals 			60-90mg/dL<br />1-hour postprandial		<140m...
Insulin and Insulin Analogs<br />
Problem with Regular Insulin<br />Slow onset of activity<br />Inconvenient for patient (administered 30-60minutes prior to...
Insulin Lispro in Pregnancy<br />More efficacious than human regular insulin to normalize blood glucose levels in gestatio...
Insulin Aspart in Pregnancy<br />The overall safety and effectiveness of insulin aspart is comparable to regular human ins...
Insulin Glulisine in Pregnancy<br />There is inadequate data on glulisine use in pregnancy.<br />
Insulin Glargine in Pregnancy<br />Glycemic control, birthweight, and prevalence of macrosomia and neonatal morbidity were...
NN304-1687: Insulin Detemir in Pregnancy Study<br />Randomised, parallel-group, open-labelled, multinational trial compari...
How to Give Insulin<br />50% of total daily insulin as basal insulin using NPH, 50% as boluses before meals with rapid ana...
How to Give Insulin<br />NPH: 1/6 of total daily insulin dose administered every 8hours<br />Lispro or Aspart: 1/6 of tota...
Continuous Subcutaneous Insulin Infusion Pump<br />CSII versus MDI in pregnancy<br />RCTs show equivalent glycemic control...
Glycemic Control and Insulin Treatment during Delivery<br />Goal: maintain normoglycemia in order to prevent neonatal hypo...
Glycemic Control and Insulin Treatment during Delivery<br />CBG >120mg/dL: 2-4 units regular insulin IV every hour that CB...
Postpartum<br />During lactation: postprandial glucose goals <150mg/dL to minimize high glucose levels in breast milk<br /...
Summary<br />Rapid achievement of normoglycemia with limited weight gain is critical to optimize maternal and fetal outcom...
Thank You!<br />
Upcoming SlideShare
Loading in...5
×

Insulin Therapy in Pregnant Women

7,501

Published on

PDA Echo

0 Comments
8 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
7,501
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
235
Comments
0
Likes
8
Embeds 0
No embeds

No notes for slide

Insulin Therapy in Pregnant Women

  1. 1. PDA ECHO: INSULIN THERAPY IN PREGNANT WOMENCynthia Halili-Manabat, M.D., PhD<br />Internal Medicine<br />October 2010<br />
  2. 2. abstract<br />goal in pregnancy complicated by diabetes is to maintain maternal glucose levels as near normal as possible throughout the pregnancy because near normal glycemia has been shown to decrease the prevalence of neonatal hypoglycaemia, macrosomia, intra-uterine death and caesarean delivery<br />steps to achieve normal glucose during pregnancy include medical nutrition therapy and the additional of insulin, if goals are not met<br />
  3. 3. abstract<br />only human NPH insulin, regular human insulin and the rapid acting insulin analogs, lispro and aspart, are approved for use during pregnancy<br />Lispro or Aspart is preferable to regular human insulin<br />fifty percent of the insulin is given as a basal dose using NPH insulin and the other 50% as boluses before meals with lispro or aspart.<br />
  4. 4. abstract<br />the total daily insulin dose may be computed based on the current weight of the patient and stage of pregnancy as follows: <br />prepregnancy, 0.6 U/kg/d<br />first trimester (wk 1-12), 0.7 U/kg/d<br />second trimester (wk 13-28), 0.8 U/kg/d<br />third trimester (wk 29-34), 0.9 U/kg/d<br />term (wk 35-39), 1.0 U/kg/d<br />these doses are only starting doses and need to be adjusted based on results of home glucose monitoring<br />
  5. 5. Fetal Hyperinsulinemia<br />LGA or macrosomia are associated with birth trauma (shoulder dystocia)<br />0.6-1.4% in fetuses weighing 2500-4000g<br />5-9% in fetuses weighing >4000g<br />Associated with neonatal hypoglycemia after infant is delivered and no longer exposed to maternal hyperglycemia<br />
  6. 6. Management of Hyperglycemia in Pregnancy<br />CGMS<br />mean fasting glucose 75mg/dL<br />peak post-prandial glucose 110mg/dL<br />Medical Nutrition Therapy<br />Weight control<br />Carbohydrate restriction<br />Frequent self-monitoring of blood glucose<br />Insulin<br />
  7. 7. When to Start Insulin<br />When MNT fails<br />Glycemic goals:<br />Premeals 60-90mg/dL<br />1-hour postprandial <140mg/dL<br />2-hour postprandial <120-130mg/dL<br />
  8. 8. Insulin and Insulin Analogs<br />
  9. 9. Problem with Regular Insulin<br />Slow onset of activity<br />Inconvenient for patient (administered 30-60minutes prior to meal)<br />Long duration of activity<br />Potential for late postprandial (4-6hours) hypoglycemia<br />Lasts up to 12hours<br />
  10. 10. Insulin Lispro in Pregnancy<br />More efficacious than human regular insulin to normalize blood glucose levels in gestational and pre-gestational diabetic women<br />Rapidly lowered postprandial glucose levels, thereby decreasing A1c levels, with fewer hypoglycemic episodes, and without increasing anti-insulin antibody levels<br />Similar neonatal outcomes versus regular insulin<br />Improved patient satisfaction<br />Especially helpful in women with hyperemesis or gastroparesis because they can be dosed after meals<br />
  11. 11. Insulin Aspart in Pregnancy<br />The overall safety and effectiveness of insulin aspart is comparable to regular human insulin in pregnant women with GDM/pregestational DM.<br />Insulin aspart was more effective than regular insulin in providing postprandial glycemic control.<br />Patients showed greater treatment satisfaction with Aspart.<br />
  12. 12. Insulin Glulisine in Pregnancy<br />There is inadequate data on glulisine use in pregnancy.<br />
  13. 13. Insulin Glargine in Pregnancy<br />Glycemic control, birthweight, and prevalence of macrosomia and neonatal morbidity were similar to human insulin<br />Rate of congenital malformations comparable to NPH insulin<br />Glargine is not approved for use in pregnancy<br />
  14. 14. NN304-1687: Insulin Detemir in Pregnancy Study<br />Randomised, parallel-group, open-labelled, multinational trial comparing the efficacy and safety of insulin detemir versus NPH insulin, used in combination with aspart as bolus insulin, in the treatment of pregnant women with type 1 diabetes<br />Expected number of 240 completed pregnancies with 120 subjects in each arm<br />To be completed 2010 <br />
  15. 15. How to Give Insulin<br />50% of total daily insulin as basal insulin using NPH, 50% as boluses before meals with rapid analog<br />Predicted total daily insulin requirement<br />Prepregnancy 0.6u/kg/d<br />First trimester 0.7u/kg/d<br />Second trimester 0.8u/kg/d<br />Third trimester 0.9u/kg/d<br />Term (wk 35-39) 1.0u/kg/d<br />Rapidly adjust dose based on SMBG<br />
  16. 16. How to Give Insulin<br />NPH: 1/6 of total daily insulin dose administered every 8hours<br />Lispro or Aspart: 1/6 of total daily insulin dose given before meals<br />Monitor BGs before and 1hour after meals<br />Goals:<br />65-90 mg/dL before meals<br /><120 mg/dL after meals<br />
  17. 17. Continuous Subcutaneous Insulin Infusion Pump<br />CSII versus MDI in pregnancy<br />RCTs show equivalent glycemic control and maternal and perinatal outcomes<br />CSII- multiple adjustable basal rates can be especially useful for patients with daytime or nocturnal hypoglycemia or a prominent dawn phenomenon<br />Disadvantages of CSII: cost, potential for marked hyperglycemia and risk of DKA as a consequence of insulin delivery failure<br />
  18. 18. Glycemic Control and Insulin Treatment during Delivery<br />Goal: maintain normoglycemia in order to prevent neonatal hypoglycemia<br />Target CGBs 80-110 mg/dL during labor<br />CBG every hour during labor, or every 2-4 hours if stable<br />CBG >100mg/dL: NS or LR at 100cc/hr<br />CBG <100mg/dL: supplemental 5% dextrose infusion at 100cc/hr<br />
  19. 19. Glycemic Control and Insulin Treatment during Delivery<br />CBG >120mg/dL: 2-4 units regular insulin IV every hour that CBG >120mg/dL (or RI incorporated into IV)<br />After expulsion of placenta, requirement of insulin will fall precipitously<br />Postpartum requirements drop to 1/3 to ½ of their previous insulin dosages; no insulin in first 24-48hours<br />
  20. 20. Postpartum<br />During lactation: postprandial glucose goals <150mg/dL to minimize high glucose levels in breast milk<br />Stimulate hyperinsulinemia and accelerate hunger in the infant<br />Contribute to excessive weight gain, obesity, and metabolic syndrome later in life<br />Human insulin and insulin analogs appear in breastmilk directly proportional to serum levels in maternal blood, but they are not absorbed in the gut<br />
  21. 21. Summary<br />Rapid achievement of normoglycemia with limited weight gain is critical to optimize maternal and fetal outcomes in all women with diabetes during pregnancy.<br />Lispro and Aspart have been tested and found to be safe and effective during pregnancy. Their use over regular insulin has been shown to result in improved glycemic control, fewer hypoglycemic episodes, and improved patient satisfaction.<br />2 to 3 doses of NPH insulin may be used to provide basal insulin needs. Neither glargine nor detemir is approved for use in pregnancy.<br />
  22. 22. Thank You!<br />
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×